Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference
September 27, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President...
Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101
September 25, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW...
Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101
September 06, 2018 07:30 ET
|
Checkpoint Therapeutics, Inc
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs Phase 3 trial in treatment-naïve EGFR...
Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President...
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
August 13, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
August 07, 2018 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics to Participate in June Investor Conferences
June 04, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
May 10, 2018 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
April 18, 2018 09:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301
March 21, 2018 08:00 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...